Department of Defense awarded the VCU Reanimation Engineering Shock Center, or VCURES, a $1.3 million cooperative agreement to study and design a way for soldiers hurt in combat to survive devastating loss of blood when medical facilities are far away. And the National Institutes of Health awarded VCURES a $1.9 million grant to study how oxygen is transported by the tiniest blood vessels of your body during severe hemorrhage and resuscitation. That strategy right now will be prolonged to change the price of oxygen make use of and delivery by organ cells at the cellular level when a soldier has experienced severe loss of blood and when blood transfusion isn’t available for several hours.Tammela, M.D., Stefano Ciatto, M.D., Vera Nelen, M.D., Maciej Kwiatkowski, M.D., Marcos Lujan, M.D., Hans Lilja, M.D., Marco Zappa, Ph.D., Louis J. Denis, M.D., Franz Recker, M.D.D.D., Chris H. Bangma, M.D., Gunnar Aus, M.D., Sigrid Carlsson, M.D., Arnauld Villers, M.D., Xavier Rebillard, M.D., Theodorus van der Kwast, M.D., Paula M. Kujala, M.D., Bert G. Blijenberg, Ph.D., Ulf-Hakan Stenman, M.D., Andreas Huber, M.D., Kimmo Taari, M.D., Matti Hakama, Ph.D., Sue M. Moss, Ph.D., Harry J. De Koning, M.D., and Anssi Auvinen, M.D. For the ERSPC Investigators: Prostate-Cancer Mortality at 11 Years of Follow-up Screening for prostate cancers has remained controversial, despite results showing a significant reduction in the rate of death from prostate cancer among males offered screening pertaining to prostate-specific antigen .1 The European Randomized Research of Screening for Prostate Cancer is a multicenter trial initiated in 1991 in the Netherlands and in Belgium, with five more European countries joining between 1994 and 1998.